Multiple endogenous receptors and cell-surface molecules on host and transplanted cells

This target designation refers to a diverse collection of cell-surface molecules primarily expressed on T-lymphocytes, including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, and HLA class I and II molecules (StatPearls, NBK538234). These proteins are essential for the complex processes of T-cell recognition, activation, and migration during an immune response. In clinical transplantation, these molecules serve as the collective target for polyclonal antibodies like Antithymocyte Globulin (ATG), which are used to prevent or treat graft rejection and graft-versus-host disease (FDA Label, Thymoglobulin). By binding to this wide array of receptors, these therapies induce rapid depletion of circulating lymphocytes and interfere with the proliferative and cytotoxic functions of the immune system (DrugBank, DB00033). This broad-spectrum approach is effective for profound immunosuppression but carries significant risks related to generalized immune deficiency and systemic inflammatory reactions.

Other names

T-lymphocyte surface antigensLymphocyte-reactive antigensThymocyte-reactive antigens

Induces T-cell depletion through complement-dependent lysis, opsonization, and apoptosis, while also modulating cell surface receptors involved in T-cell activation and leukocyte adhesion.